- Published on
Urology – Prostate Cancer: Epidemiology, Risk Factors, Genetics, Diagnosis, Staging, and Management
1. Definition and Clinical Overview
Prostate cancer (CaP) refers to malignant neoplasia arising within the prostate gland.
More than 95% of prostate cancers are adenocarcinomas, while other histological types are uncommon.
Prostate adenocarcinoma generally originates from glandular epithelial cells and most frequently develops in the peripheral zone.
Main Clinical Categories
- Localized prostate cancer.
- Locally advanced prostate cancer.
- Regional lymph node-positive disease.
- Metastatic hormone-sensitive prostate cancer.
- Nonmetastatic castration-resistant prostate cancer.
- Metastatic castration-resistant prostate cancer.
Clinical Importance
Prostate cancer demonstrates marked biological variability.
Some tumours progress slowly and may never cause symptoms, whereas others are aggressive and may metastasize early.
Key Principle: Prostate Cancer Management Must Be Individualized According To Tumour Risk, Clinical Stage, Life Expectancy, Comorbidities, And Patient Preferences.
2. Epidemiology
Incidence
Prostate cancer is among the most commonly diagnosed solid malignancies in men.
Historical United States Statistics, 2014
The source reports:
- 233,000 new cases.
- 29,480 deaths.
These are historical figures rather than current annual estimates.
PSA Screening Era
Widespread use of prostate-specific antigen testing caused a marked increase in reported prostate cancer incidence between:
1989 and 1992.
Clinical Explanation
PSA testing increased detection of cancers that previously may not have been diagnosed during life.
Historical Mortality Trends
The source describes a significant reduction in mortality after 1991.
This trend reflects multiple possible contributors, including:
- Earlier diagnosis.
- Improved treatment.
- Changes in population risk and clinical management.
Historical Five-Year Relative Survival
Approximately:
100%.
Important Qualification
This estimate largely reflects the very favorable survival of patients diagnosed with localized or regional disease.
Patients with distant metastatic disease have substantially less favorable outcomes.
Historical Lifetime Risk
Approximately:
16.15%.
Important Qualification
Lifetime risk depends on population, age, screening practices, and other factors.
3. Population and Geographic Variation
The historical source reports particularly high incidence among African American men.
Historical Relative Incidence
Approximately:
Twice That Of White American Men.
The source also describes lower incidence in several Asian populations.
Historical Example
China:
1.9 Cases per 100,000 Men per Year.
Migration Studies
The source notes increased prostate cancer incidence among Asian men who migrate to the United States.
Clinical Interpretation
Geographic and population differences suggest contributions from:
- Genetic susceptibility.
- Environmental exposures.
- Lifestyle.
- Screening practices.
- Healthcare access.
Important Qualification
The historical incidence figures should not be applied directly to modern populations. Ancestry-associated risk is not deterministic for an individual patient.
4. Risk Factors
Prostate cancer development involves genetic, hormonal, environmental, and age-related influences.
Main Risk Factors
- Increasing age.
- Family history.
- Inherited cancer-predisposition variants.
- African ancestry in population-based epidemiological studies.
- Other environmental and biological factors.
5. Family History
Clinical Significance
Risk increases according to:
- Number of affected relatives.
- Degree of biological relationship.
- Age at diagnosis.
- Presence of associated hereditary cancers.
Particularly Important
A first-degree relative with prostate cancer.
Clinical Importance
A Strong Family History, Particularly Early-Onset Prostate Cancer In Close Relatives, Raises Concern For Inherited Susceptibility.
6. Inflammation and Infection
The historical source identifies possible associations with:
- Prostatitis.
- Sexually transmitted infections.
- Chronic inflammation.
Proposed Mechanisms
- Persistent epithelial injury.
- Inflammatory mediators.
- Oxidative stress.
- Increased cellular turnover.
Important Qualification
Associations between prostatitis, infection, and prostate cancer have been inconsistent across studies.
Chronic prostatitis is not an established direct cause of prostate cancer in every affected patient.
7. Oxidative Stress
Proposed Mechanism
Oxidative injury may damage cellular DNA.
Relevant Biological Processes
- Reactive oxygen species production.
- DNA damage.
- Cellular repair mechanisms.
- Accumulation of mutations.
Clinical Importance
Some genes investigated in prostate cancer susceptibility participate in oxidative damage repair.
8. Dietary Factors
The historical source identifies a Western dietary pattern characterized by:
- High meat consumption.
- High dairy intake.
- Increased saturated fat.
Other Historical Associations
- Folate supplementation.
- Dietary antioxidant status.
Important Qualification
Associations between individual foods or supplements and prostate cancer are not equivalent to proven causation.
There is no established dietary supplement that reliably prevents prostate cancer.
9. Androgens
Physiological Role
Androgens are essential for normal development and function of the prostate gland.
Principal Hormone
Testosterone.
Important Active Metabolite
Dihydrotestosterone (DHT).
Biological Effects
Androgen signaling influences:
- Prostatic epithelial growth.
- Glandular differentiation.
- Cellular survival.
- Prostate cancer progression.
Clinical Importance
Androgen Receptor Signaling Is Central To Prostate Cancer Biology And Forms The Basis Of Hormonal Treatment For Advanced Disease.
10. Androgen Receptor Genetics
The source describes variation in the CAG repeat sequence of the androgen receptor gene.
Historical Association
Shorter CAG repeat length was associated with increased prostate cancer susceptibility in some studies.
Important Qualification
The clinical value of androgen receptor CAG repeat testing remains limited and is not part of routine prostate cancer risk assessment.
11. Other Hormonal Factors
Estrogens
May influence prostate growth and cancer biology.
The historical source describes mixed effects.
Insulin-Like Growth Factor 1
IGF-1.
Investigated in relation to cancer cell proliferation and survival.
Vitamin D
The original chapter proposes a protective effect.
Important Qualification
A protective clinical effect of vitamin D supplementation against prostate cancer has not been established.
Vitamin D supplementation should not be prescribed specifically to prevent prostate cancer without another appropriate indication.
12. Genetics of Prostate Cancer
General Principles
Prostate cancer may be:
- Sporadic.
- Familial.
- Associated with inherited pathogenic variants.
The multifocal and heterogeneous nature of prostate cancer complicates genetic research.
13. Historical HPC1 Gene Association
Location
Chromosome 1.
The source describes the hereditary prostate cancer susceptibility region HPC1.
Associated Gene
RNASEL.
Proposed Mechanism
Disruption of antiviral and cellular RNA-related pathways may contribute to susceptibility.
Important Qualification
Historical candidate-gene associations have not all proved sufficiently predictive for routine clinical testing.
14. Other Historical Candidate Genes
The original source lists:
- TP53.
- ELAC2/HPC2.
- MSR1.
- CHEK2.
- BRCA2.
- PON1.
- OGG1.
- MIC1.
Clinical Importance
These genes were investigated because of their roles in:
- DNA repair.
- Tumour suppression.
- Oxidative stress responses.
- Cellular regulation.
15. Contemporary Hereditary Prostate Cancer Genetics
Important established cancer-predisposition genes include:
- BRCA2.
- BRCA1.
- ATM.
- CHEK2.
- HOXB13.
- Mismatch-repair genes associated with Lynch syndrome.
Mismatch-Repair Genes
- MLH1.
- MSH2.
- MSH6.
- PMS2.
Clinical Importance
BRCA2 Pathogenic Variants Are Particularly Important Because They May Increase The Risk Of Aggressive Prostate Cancer And Can Influence Screening And Treatment.
16. Genetic Counseling and Testing
Potential Indications
- Strong family history of prostate cancer.
- Multiple hereditary cancer diagnoses in the family.
- Known familial pathogenic variant.
- Selected high-risk prostate cancers.
- Metastatic prostate cancer.
- Tumour findings suggesting hereditary DNA repair deficiency.
Clinical Importance
Germline testing may influence:
- Family counseling.
- Screening strategies.
- Treatment planning.
- Eligibility for targeted therapy.
17. Familial Versus Sporadic Disease
The original source reports that familial prostate cancer may follow a clinical course similar to sporadic disease.
Important Qualification
Disease behavior varies according to the underlying genetic alteration.
Some inherited pathogenic variants, particularly BRCA2, are associated with more aggressive disease.
18. Normal Prostate Anatomy and Function
Historical Adult Prostate Weight
Approximately:
20–25 g.
Secretory Function
The prostate contributes fluid to semen.
Historical Contribution
Approximately:
30% of Ejaculate Volume.
Clinical Importance
Knowledge of prostate anatomy is central to understanding cancer distribution, biopsy sampling, and treatment complications.
19. Prostate Zones
Peripheral Zone
Most prostate adenocarcinomas arise in this zone.
Transition Zone
A common location for benign prostatic hyperplasia.
Prostate cancer may also arise here.
Central Zone
Less frequently the primary site of prostate cancer.
Clinical Importance
The Peripheral Zone Is The Most Common Site Of Prostate Adenocarcinoma.
20. Pathophysiology of Prostate Adenocarcinoma
General Mechanism
Malignant transformation involves progressive molecular and cellular changes.
Important Processes
- Genetic abnormalities.
- Altered growth signaling.
- Disruption of cell-cycle regulation.
- Loss of normal glandular organization.
- Invasive growth.
- Potential metastatic spread.
21. High-Grade Prostatic Intraepithelial Neoplasia
HGPIN.
Definition
Atypical proliferation of prostatic glandular epithelial cells within pre-existing ducts and acini, with preservation of the basal cell layer.
Historical Subsequent Cancer Detection Risk
16–44%.
Historical Recommendation
Repeat biopsy within one year was not always necessary in the absence of other suspicious findings.
Contemporary Clinical Importance
Isolated Focal HGPIN On An Adequate Prostate Biopsy Does Not Automatically Require Immediate Repeat Biopsy.
Further assessment depends on:
- PSA.
- MRI.
- Extent of HGPIN.
- Previous sampling.
- Other cancer risk factors.
22. Atypical Small Acinar Proliferation
ASAP.
Definition
Small atypical prostate glands suspicious for adenocarcinoma but insufficient for a definitive cancer diagnosis.
Historical Cancer Detection Risk on Subsequent Biopsy
42–49%.
Clinical Importance
ASAP requires additional evaluation because clinically significant cancer may have been missed.
Contemporary Approach
Consider:
- Repeat PSA assessment.
- Prostate MRI.
- Targeted and systematic sampling.
- Repeat biopsy when indicated.
Important Qualification
ASAP is not equivalent to a confirmed malignant diagnosis or a distinct obligatory premalignant lesion.
23. Histological Types of Prostate Cancer
Adenocarcinoma
The dominant histological type.
Frequency
More Than 95%.
Less Common Malignancies
- Urothelial carcinoma involving the prostate.
- Small-cell or neuroendocrine carcinoma.
- Sarcoma.
- Other rare malignant tumours.
Clinical Importance
Some aggressive nonadenocarcinoma variants may progress without substantial PSA elevation.
24. Histopathology of Adenocarcinoma
Main Microscopic Findings
- Crowded, irregular glands.
- Loss of normal glandular architecture.
- Prominent nucleoli.
- Nuclear enlargement.
- Infiltrative growth.
Characteristic Diagnostic Finding
Absence of the basal cell layer.
Clinical Importance
Basal cell immunohistochemistry may help distinguish conventional adenocarcinoma from benign or atypical glands.
25. Gleason Grading
General Principle
The Gleason system grades prostate adenocarcinoma according to glandular architecture.
Historical Scale
Patterns 1–5.
Gleason Score
The primary and secondary histological patterns are combined.
Examples
- Gleason 3 + 3 = 6.
- Gleason 3 + 4 = 7.
- Gleason 4 + 3 = 7.
- Gleason 4 + 4 = 8.
- Gleason 4 + 5 = 9.
Important Qualification
Gleason patterns 1 and 2 are not used in routine contemporary needle-biopsy grading.
26. ISUP Grade Groups
Grade Group 1
Gleason 3 + 3 = 6.
Grade Group 2
Gleason 3 + 4 = 7.
Grade Group 3
Gleason 4 + 3 = 7.
Grade Group 4
Gleason Score 8.
Grade Group 5
Gleason Scores 9–10.
Clinical Importance
Gleason 4 + 3 Is More Aggressive Than Gleason 3 + 4 Despite Both Having A Total Score Of Seven.
27. Cribriform and Intraductal Histology
Contemporary Significance
Cribriform carcinoma and intraductal carcinoma of the prostate are important adverse pathological findings.
Clinical Importance
Their presence may affect eligibility for active surveillance.
Contemporary European guidance recommends excluding patients with these histological patterns from routine active surveillance.
28. Clinical Presentation
General Principles
Early localized prostate cancer is frequently asymptomatic.
Common Detection Methods
- PSA testing.
- Digital rectal examination.
- MRI.
- Biopsy following risk assessment.
Clinical Importance
Most Localized Prostate Cancers Do Not Produce Specific Urinary Symptoms.
29. Local Urinary Symptoms
Occasional symptoms include:
- Weak urinary stream.
- Hesitancy.
- Frequency.
- Urgency.
- Incomplete bladder emptying.
- Urinary retention.
Important Qualification
These symptoms are often caused by benign prostatic hyperplasia rather than prostate cancer.
30. Other Local Symptoms
Possible presentations include:
- Hematuria.
- Hematospermia.
- Erectile dysfunction.
- Pelvic discomfort.
Clinical Importance
These findings are nonspecific and require appropriate differential diagnosis.
31. Metastatic Symptoms
Advanced disease may present with:
- Bone pain.
- Weight loss.
- Fatigue.
- Malaise.
- Pathological fractures.
- Neurological deficits.
32. Spinal Cord Compression
Mechanism
Metastatic tumour may compress the spinal cord or cauda equina.
Possible Manifestations
- Severe back pain.
- Limb weakness.
- Sensory changes.
- Urinary retention.
- Bowel dysfunction.
- Paralysis.
Clinical Importance
Suspected Metastatic Spinal Cord Compression Is An Oncological Emergency Requiring Urgent Assessment And Treatment.
33. Physical Examination
Digital Rectal Examination
DRE.
Suspicious Findings
- Hard nodules.
- Induration.
- Asymmetry.
- Irregular gland contour.
Clinical Importance
An abnormal DRE increases the suspicion of prostate cancer.
Important Limitation
A normal DRE does not exclude clinically significant cancer.
34. PSA Testing
Definition
Prostate-specific antigen is a protein secreted by prostatic epithelial cells.
Principal Uses
- Prostate cancer risk assessment.
- Treatment response monitoring.
- Detection of biochemical recurrence.
- Assessment of disease progression.
Important Principle
PSA Is Organ-Specific But Not Cancer-Specific.
35. Causes of Elevated PSA
Important causes include:
- Prostate cancer.
- Benign prostatic hyperplasia.
- Prostatitis.
- Urinary tract inflammation.
- Recent urinary retention.
- Some forms of prostatic manipulation.
Clinical Importance
An elevated PSA requires interpretation within the clinical context.
36. PSA Screening
Historical Source
The original chapter describes controversy regarding PSA screening because sensitivity and specificity are imperfect.
Main Potential Benefit
Earlier detection of clinically significant prostate cancer.
Main Potential Harms
- False-positive results.
- Unnecessary imaging.
- Unnecessary biopsy.
- Overdiagnosis.
- Overtreatment.
- Treatment-related urinary and sexual complications.
37. Contemporary Risk-Adapted Screening
Current European guidance supports offering informed PSA testing based on individual risk.
Typical Starting Ages
- 50 years: Men at average risk.
- 45 years: Men of African descent.
- 45 years: Men with relevant early family history.
- 40 years: Men carrying BRCA2 pathogenic variants.
Important Qualification
Screening decisions should also account for life expectancy and personal preferences.
38. Life Expectancy and Screening
Patients with limited life expectancy may be unlikely to benefit from detecting asymptomatic localized prostate cancer.
Contemporary Clinical Principle
Routine early-detection testing is generally discouraged in asymptomatic men whose life expectancy is below approximately 10–15 years.
Important Qualification
Symptomatic patients require appropriate clinical assessment regardless of screening eligibility.
39. PSA Velocity
Definition
The rate of PSA change over time.
Historical Adverse Threshold
Greater Than 2 ng/mL per Year.
The source associates this with poorer outcomes after treatment.
Important Contemporary Qualification
PSA velocity should not be used as the sole indication for prostate biopsy.
40. Percentage Free PSA
Definition
The proportion of PSA circulating in unbound form.
Clinical Interpretation
Lower Percentage Free PSA Is Associated With Greater Probability Of Prostate Cancer in selected patients with moderately elevated PSA.
Clinical Importance
Can contribute to risk assessment when the decision to biopsy remains uncertain.
41. PSA Density
Definition
PSA concentration divided by prostate volume.
Formula
PSA Density = Serum PSA / Prostate Volume.
Typical Units
ng/mL/cm³.
Clinical Importance
Higher PSA density increases suspicion for clinically significant prostate cancer.
A historical commonly used threshold is:
0.15 ng/mL/cm³.
Important Qualification
Interpretation depends on MRI findings and the complete risk profile.
42. Additional Laboratory Markers
Prostatic Acid Phosphatase
Historically used in prostate cancer evaluation.
Clinical Role
Limited in contemporary routine practice.
Alkaline Phosphatase
May be elevated in patients with osteoblastic bone metastases.
Important Qualification
An elevated alkaline phosphatase is not specific for metastatic prostate cancer.
43. Initial Diagnostic Approach
Modern Clinical Sequence
- Assess PSA and clinical risk factors.
- Repeat an unexpectedly elevated PSA when appropriate.
- Perform DRE.
- Consider validated risk calculators or adjunctive biomarkers.
- Obtain prebiopsy prostate MRI when indicated.
- Determine whether biopsy is necessary.
- Perform targeted or systematic sampling as appropriate.
- Establish pathological Grade Group.
- Complete stage-appropriate metastatic evaluation.
44. Multiparametric Prostate MRI
Clinical Role
Contemporary MRI helps:
- Detect suspicious lesions.
- Estimate lesion extent.
- Identify clinically significant cancer.
- Guide prostate biopsy.
- Assist local staging.
Important Sequences
- T2-weighted imaging.
- Diffusion-weighted imaging.
- Apparent diffusion coefficient maps.
- Dynamic contrast-enhanced imaging when used.
45. PI-RADS
Definition
Prostate Imaging Reporting and Data System.
Interpretation
PI-RADS scores range from 1 to 5.
- PI-RADS 1–2: Low suspicion.
- PI-RADS 3: Equivocal.
- PI-RADS 4: High suspicion.
- PI-RADS 5: Very high suspicion.
Clinical Importance
MRI Findings Help Determine Whether Prostate Biopsy Is Appropriate And Where Samples Should Be Obtained.
46. Transrectal Ultrasound
TRUS.
Historical Role
Used principally to guide needle biopsy.
Classical Ultrasound Finding
Hypoechoic peripheral-zone nodule.
Important Qualification
Cancer may be:
- Hypoechoic.
- Isoechoic.
- Hyperechoic.
TRUS alone cannot reliably exclude malignancy.
47. Prostate Biopsy
Historical Standard
10–12 Systematic Cores.
Important Sampling Regions
- Base.
- Mid-gland.
- Apex.
- Posterolateral peripheral zone.
48. MRI-Targeted Biopsy
Current Role
Sampling directed toward lesions identified on prostate MRI.
Main Methods
- Cognitive targeting.
- MRI–ultrasound fusion.
- In-bore MRI-guided biopsy.
Contemporary Consideration
Targeted biopsy may be combined with perilesional or systematic sampling according to MRI and clinical risk.
49. Transperineal Biopsy
Definition
Needle biopsy performed through the perineal skin.
Main Advantage
Reduced exposure to rectal bacteria.
Clinical Importance
Transperineal Biopsy Is Preferred In Contemporary European Guidance Because Of Its Lower Infectious Risk.
50. Pathological Staging
TNM System
Prostate cancer is staged according to:
- Primary tumour extent: T.
- Regional lymph node involvement: N.
- Distant metastatic spread: M.
51. T1 Disease
General Definition
Clinically inapparent tumour not palpable on examination.
T1a and T1b
Cancer identified incidentally in resected prostate tissue.
T1c
Cancer detected through needle biopsy, typically after an elevated PSA.
Historical Observation
The source reports approximately 75% of newly diagnosed prostate cancers as T1c in some screening-era populations.
52. T2 Disease
Definition
Tumour confined within the prostate.
Clinical Importance
Potentially suitable for curative local treatment or active surveillance depending on risk.
53. T3 Disease
T3a
Extraprostatic extension.
T3b
Seminal vesicle invasion.
Clinical Importance
Associated with greater risk of recurrence and progression.
54. T4 Disease
Definition
Tumour invades adjacent structures beyond the seminal vesicles.
Clinical Importance
Represents locally advanced disease.
55. Nodal and Metastatic Classification
N1
Regional lymph node involvement.
M1a
Nonregional lymph node metastases.
M1b
Bone metastases.
M1c
Metastasis to other sites, with or without bone involvement.
56. Patterns of Spread
Direct Extension
Prostate cancer can extend beyond the gland into nearby tissues.
Important Routes
- Perineural spaces.
- Lymphovascular channels.
- Direct local invasion.
Regional Spread
Pelvic lymph nodes.
Distant Spread
Most commonly bone.
Other possible sites include:
- Lung.
- Liver.
- Central nervous system in advanced disease.
57. Bone Metastases
Classical Pattern
Osteoblastic metastases.
Typical Sites
- Spine.
- Pelvis.
- Ribs.
- Other axial skeletal structures.
Clinical Consequences
- Bone pain.
- Pathological fracture.
- Spinal cord compression.
Important Qualification
Prostate cancer metastases may also be mixed or predominantly lytic in selected cases.
58. Staging Investigations
Historical Approach
The source recommends:
- CT abdomen and pelvis.
- Bone scintigraphy.
Particularly for intermediate-risk and high-risk disease.
Historical Imaging Triggers
- PSA greater than 10 ng/mL.
- Gleason score 7 or greater.
- Clinical stage T2b or higher.
Important Qualification
These thresholds are historical and should not be used as universal indications for current imaging.
59. PSMA PET/CT
Contemporary Role
Prostate-specific membrane antigen PET/CT provides sensitive evaluation of metastatic prostate cancer.
Important Applications
- Pelvic lymph node assessment.
- Distant lymph node staging.
- Bone metastasis detection.
- Restaging recurrent disease.
Clinical Importance
PSMA PET/CT Is A Preferred Staging Investigation For High-Risk Localized And Locally Advanced Prostate Cancer When Available.
60. Risk Stratification
Risk grouping combines:
- PSA.
- Grade Group.
- Clinical T stage.
- Extent of disease.
61. Historical Low-Risk Disease
The original source describes:
- Clinical stage T1–T2a.
- Gleason score 6 or lower.
- PSA below 10 ng/mL.
Contemporary Interpretation
Generally corresponds to ISUP Grade Group 1 and favorable clinical features.
62. Historical Intermediate-Risk Disease
The source describes:
- Clinical stage T2b–T2c.
- Gleason score 7.
- PSA 10–20 ng/mL.
Contemporary Qualification
Intermediate-risk disease is now separated into favorable and unfavorable groups.
63. Historical High-Risk Disease
The original source describes:
- Stage T3a or greater.
- Gleason score 8–10.
- PSA greater than 20 ng/mL.
Important Qualification
Modern classifications more precisely distinguish high-risk localized from locally advanced disease.
64. Contemporary Risk Groups
Low Risk
Generally characterized by:
- ISUP Grade Group 1.
- PSA below 10 ng/mL.
- Organ-confined clinical stage.
Favorable Intermediate Risk
May include:
- ISUP Grade Group 2 with favorable PSA and clinical stage.
- Selected Grade Group 1 disease with PSA 10–20 ng/mL.
Unfavorable Intermediate Risk
May include:
- Grade Group 3.
- Grade Group 2 with additional adverse features.
High Risk
May include:
- Grade Group 4–5.
- PSA greater than 20 ng/mL.
Locally Advanced
Includes:
- cT3–T4 disease.
- Regional nodal disease in the relevant clinical classification.
Clinical Importance
Risk Stratification Determines Whether Active Surveillance, Local Treatment, Combined-Modality Treatment, Or Systemic Therapy Is Most Appropriate.
65. Differential Diagnosis
Benign Prostatic Hyperplasia
Can cause:
- Elevated PSA.
- Urinary symptoms.
- Enlarged prostate.
Prostatitis
May be:
- Acute.
- Chronic.
- Granulomatous.
Clinical Importance
Inflammation may mimic malignancy through PSA elevation or abnormal MRI findings.
Recent Instrumentation
May be associated with temporary PSA changes in selected circumstances.
Other Prostate Malignancies
- Urothelial carcinoma.
- Sarcoma.
- Neuroendocrine carcinoma.
66. Differential Diagnosis of Metastatic Findings
Bone Disease
- Paget disease.
- Other malignant bone lesions.
- Other causes of abnormal bone imaging.
Lymphadenopathy
- Lymphoma.
- Tuberculosis.
- Other infections.
- Nonprostatic metastatic malignancy.
67. General Treatment Principles
Management is determined by:
- Cancer risk group.
- Clinical stage.
- Life expectancy.
- Overall health.
- Urinary function.
- Sexual function.
- Patient preference.
Main Treatment Categories
- Active surveillance.
- Watchful waiting.
- Radical prostatectomy.
- Radiotherapy.
- Selected focal or ablative therapies.
- Androgen-deprivation therapy.
- Systemic therapy.
68. Active Surveillance
Definition
A structured monitoring strategy for prostate cancer with favorable biological characteristics.
Main Objective
Avoid unnecessary treatment while preserving the opportunity for curative treatment if clinically meaningful progression occurs.
69. Ideal Active Surveillance Candidates
The historical source describes:
- PSA below 10 ng/mL.
- Clinical stage T1c.
- Gleason score 6 or lower.
- Fewer than three positive biopsy cores.
- Less than 50% cancer involvement in each core.
- PSA density below 0.15 ng/mL/cm³.
Important Qualification
These represent historical highly selective inclusion criteria.
Modern MRI-informed active surveillance is broader in some circumstances.
70. Contemporary Active Surveillance
Standard Indication
Low-Risk Localized Prostate Cancer.
Selected Additional Indication
Carefully selected favorable intermediate-risk disease, including some Grade Group 2 tumours.
Important Requirements
- Low cancer volume.
- Favorable pathological features.
- Appropriate MRI findings.
- Ability to comply with surveillance.
- Informed patient preference.
71. Active Surveillance Monitoring
Contemporary European guidance includes:
- PSA at least every six months.
- Clinical review.
- MRI when indicated.
- Repeat biopsy according to protocol and risk.
Important Principle
Changes In PSA Or MRI Should Prompt Reassessment, But Definitive Treatment Decisions Generally Require Confirmation Of Clinically Meaningful Disease Progression.
72. Watchful Waiting
Definition
A less intensive management strategy focused on symptom control rather than routine attempts to cure the cancer.
Main Candidates
Patients with:
- Limited life expectancy.
- Significant comorbidities.
- Low likelihood of benefiting from curative treatment.
Clinical Importance
Watchful Waiting Is Not The Same As Active Surveillance.
73. Radical Prostatectomy
Definition
Surgical removal of:
- Prostate gland.
- Seminal vesicles.
Followed by reconstruction of urinary continuity between the bladder and urethra.
Main Goal
Curative treatment of appropriate localized or selected locally advanced disease.
74. Surgical Approaches
The historical source describes:
- Open retropubic surgery.
- Open perineal surgery.
- Laparoscopic surgery.
- Robot-assisted laparoscopic surgery.
Clinical Importance
Choice of technique depends on surgical expertise, anatomy, and clinical circumstances.
75. Robot-Assisted Radical Prostatectomy
Potential Benefits
- Reduced blood loss.
- Shorter hospitalization in some settings.
- Enhanced visualization.
- Minimally invasive access.
Important Qualification
Long-term oncological and functional outcomes depend heavily on surgeon experience and patient characteristics.
Robotic surgery does not guarantee superior cancer control.
76. Nerve-Sparing Surgery
Clinical Goal
Preserve erectile function by protecting relevant neurovascular structures.
Important Requirement
Nerve preservation must be oncologically appropriate.
Clinical Importance
Nerve-Sparing Radical Prostatectomy Should Be Considered When Cancer Extent Permits Safe Preservation Of Neurovascular Structures.
77. Pelvic Lymph Node Dissection
Clinical Role
Provides pathological nodal staging in selected patients.
Important Considerations
- Recurrence risk.
- Probability of nodal involvement.
- Surgical morbidity.
- Overall treatment plan.
78. Complications of Radical Prostatectomy
Important complications include:
- Urinary incontinence.
- Erectile dysfunction.
- Bleeding.
- Infection.
- Anastomotic stricture.
- Lymphocele following nodal dissection.
- Other surgical complications.
79. Radiation Therapy
Main Modalities
- External-beam radiotherapy.
- Brachytherapy.
Clinical Objective
Deliver a tumouricidal radiation dose while limiting damage to surrounding tissues.
80. External-Beam Radiotherapy
Historical Techniques
The source emphasizes:
- Intensity-modulated radiotherapy.
- Image-guided radiotherapy.
Contemporary Techniques
- IMRT.
- VMAT.
- IGRT.
Clinical Importance
Modern radiation planning allows improved dose conformity and sparing of adjacent normal structures.
81. Hypofractionated Radiotherapy
Definition
Radiation delivered using larger doses per fraction over fewer treatment sessions.
Historical Position
The source describes hypofractionation as being investigated in clinical trials.
Contemporary Qualification
Moderately Hypofractionated Radiotherapy Is An Established Standard Treatment Option For Appropriate Patients With Localized Prostate Cancer.
Selected patients may also receive stereotactic body radiotherapy.
82. Proton Beam Therapy
Clinical Principle
Uses proton particles to deliver radiation.
Historical Source
Describes increasing support for the technique.
Important Qualification
Proton therapy has not demonstrated consistent clinical superiority over high-quality modern photon radiotherapy for all prostate cancer patients.
83. Brachytherapy
Definition
Radiation delivered using radioactive sources placed within the prostate.
Two Main Types
- Low-dose-rate brachytherapy.
- High-dose-rate brachytherapy.
84. Low-Dose-Rate Brachytherapy
LDR.
Historical Radioisotopes
- Iodine-125.
- Palladium-103.
Method
Permanent radioactive seeds placed into the prostate.
Historical Selection
Low-risk disease with prostate volume below approximately 60 g.
Important Qualification
Prostate volume is one of several selection factors rather than an absolute universal threshold.
85. High-Dose-Rate Brachytherapy
HDR.
Historical Radioisotope
Iridium-192.
Method
Temporary catheters deliver a high radiation dose directly to the prostate.
Clinical Role
May be used alone or with external-beam radiotherapy in selected patients.
86. Radiotherapy Plus ADT
General Principle
Combining radiation with androgen suppression improves outcomes in selected intermediate-risk and high-risk patients.
87. Intermediate-Risk Radiotherapy
Typical ADT Duration
Approximately:
4–6 Months
when ADT is indicated.
Important Qualification
Selected favorable intermediate-risk patients may not require ADT.
88. High-Risk Radiotherapy
Typical ADT Duration
Approximately:
2–3 Years.
Clinical Importance
Long-Term ADT Combined With Definitive Radiotherapy Is A Standard Treatment Strategy For Appropriate High-Risk Localized Prostate Cancer.
89. Locally Advanced and Node-Positive Disease
Treatment often involves combined modalities.
Possible Components
- Radiation to the prostate.
- Pelvic nodal radiation.
- Long-term ADT.
- Selected treatment intensification.
Contemporary Consideration
Abiraterone plus corticosteroid may be added in eligible patients with specified high-risk nonmetastatic or node-positive disease.
90. Cryotherapy
Definition
Destruction of prostate tissue through freezing and thawing.
Historical Source
Describes placement of multiple cryoprobes under ultrasound guidance.
Clinical Importance
The freezing zone is monitored to limit damage to adjacent structures.
Contemporary Qualification
Whole-gland or focal cryotherapy is not considered routine standard primary treatment for all localized prostate cancers.
European guidance restricts its use to clinical trials or registries.
91. High-Intensity Focused Ultrasound
HIFU.
Definition
Focused ultrasound energy produces thermal tissue destruction.
Historical Source
Describes HIFU as investigational.
Contemporary Qualification
HIFU remains a selected ablative option with less mature long-term comparative evidence than established surgery or radiation.
92. Metastatic Prostate Cancer
General Principle
Most metastatic prostate adenocarcinomas initially remain sensitive to androgen suppression.
Clinical Category
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
93. Androgen-Deprivation Therapy
ADT.
Main Goal
Reduce androgen signaling and suppress prostate cancer growth.
Main Methods
- GnRH agonists.
- GnRH antagonists.
- Bilateral orchiectomy.
94. GnRH Agonists
Historical Examples
- Leuprolide.
- Goserelin.
- Triptorelin.
- Histrelin.
Mechanism
Continuous stimulation of pituitary GnRH receptors eventually suppresses:
- LH.
- FSH.
Consequence
Reduced testicular testosterone production.
95. Testosterone Flare
GnRH agonists initially increase testosterone before suppression occurs.
Potential Complications
- Bone pain exacerbation.
- Urinary obstruction.
- Worsening metastatic symptoms.
- Spinal cord compression in susceptible patients.
Historical Prevention
Oral antiandrogen treatment initiated before the first GnRH agonist dose.
96. GnRH Antagonists
Historical Example
Degarelix.
Contemporary Additional Example
Relugolix.
Mechanism
Direct blockade of pituitary GnRH receptors.
Main Advantage
Rapid testosterone suppression without initial agonist-related flare.
97. Bilateral Orchiectomy
Definition
Surgical removal of both testes.
Clinical Effect
Rapid and permanent reduction of testosterone production.
Advantages
- No need for ongoing medical castration injections.
- Rapid androgen suppression.
Limitations
- Irreversible.
- Sexual side effects.
- Psychological implications.
98. Antiandrogens
Historical Examples
- Flutamide.
- Bicalutamide.
- Nilutamide.
Mechanism
Block androgen receptor activity.
Historical Role
Often used alongside GnRH agonists.
Contemporary Qualification
First-generation antiandrogen monotherapy is generally not the preferred systemic treatment for metastatic disease.
99. Contemporary Treatment of mHSPC
Main Principle
ADT Alone Is Generally Insufficient For Fit Patients With Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.
Treatment intensification improves survival in appropriate patients.
100. ADT Plus Androgen Receptor Pathway Inhibitors
Important options include:
- Abiraterone plus prednisone or prednisolone.
- Enzalutamide.
- Apalutamide.
- Darolutamide in selected circumstances.
Clinical Importance
Combination Therapy Is A Standard Approach For Most Eligible Patients With Metastatic Hormone-Sensitive Prostate Cancer.
101. Docetaxel
Drug Class
Taxane chemotherapy.
Mechanism
Interferes with microtubule function.
Clinical Role
Used in selected metastatic prostate cancer settings.
Contemporary mHSPC Context
Docetaxel is commonly considered as part of intensified combination treatment in appropriately selected fit patients.
102. Triplet Therapy
Definition
Combination of:
- ADT.
- Docetaxel.
- An androgen receptor pathway inhibitor.
Important Examples
- ADT + docetaxel + darolutamide.
- ADT + docetaxel + abiraterone.
Clinical Importance
Triplet therapy may benefit selected patients, particularly those with substantial metastatic disease burden.
103. Prostate Radiation in Metastatic Disease
Selected patients with newly diagnosed low-volume metastatic disease may benefit from radiation to the prostate.
Clinical Importance
Treatment Of The Primary Prostate Tumour Can Improve Outcomes In Selected Patients With Low-Volume De Novo Metastatic Disease.
104. Castration-Resistant Prostate Cancer
CRPC.
Definition
Prostate cancer that progresses despite appropriately suppressed testosterone.
Historical Castration Threshold
Testosterone Below 50 ng/dL.
Clinical Progression
May involve:
- Increasing PSA.
- Radiological progression.
- Clinical progression.
105. Nonmetastatic CRPC
Definition
Castration-resistant disease without detectable distant metastases on the specified imaging assessment.
Important Prognostic Factor
PSA doubling time.
Contemporary Treatment Options
Selected high-risk patients may receive:
- Apalutamide.
- Enzalutamide.
- Darolutamide.
Generally while continuing ADT.
106. Metastatic CRPC
mCRPC.
General Principle
Disease progresses despite castrate testosterone and has evidence of metastatic spread.
Main Treatment Categories
- Androgen receptor pathway inhibitors.
- Taxane chemotherapy.
- PARP inhibitors in molecularly selected patients.
- Radioligand therapy.
- Radium-223 in selected bone-metastatic disease.
- Immunotherapy in selected circumstances.
107. Historical Ketoconazole Therapy
Historical Mechanism
Inhibition of adrenal and gonadal androgen synthesis.
Historical Use
Secondary hormonal manipulation.
Contemporary Qualification
Ketoconazole has largely been superseded by more selective and effective therapies, including abiraterone.
108. Abiraterone
Mechanism
Inhibits CYP17-dependent androgen synthesis.
Clinical Importance
Reduces androgen production from:
- Adrenal glands.
- Testicular sources.
- Tumour-associated pathways.
Important Requirement
Administered with an appropriate corticosteroid regimen.
109. Enzalutamide
Drug Class
Androgen receptor signaling inhibitor.
Mechanism
Blocks multiple aspects of androgen receptor activity.
Clinical Role
Used in several advanced prostate cancer settings according to disease stage and prior treatment.
110. Docetaxel and Cabazitaxel
Docetaxel
A taxane used in metastatic prostate cancer.
Cabazitaxel
Another taxane, particularly relevant after selected previous therapies, including docetaxel.
Important Toxicities
- Myelosuppression.
- Neutropenia.
- Infection.
- Fatigue.
- Neuropathy.
111. Sipuleucel-T
Definition
Autologous cellular immunotherapy.
Historical Source Indication
Asymptomatic or minimally symptomatic metastatic CRPC.
Contemporary Qualification
An option for appropriately selected patients where available, particularly in the United States.
112. Radium-223
Mechanism
A bone-targeting alpha-emitting radiopharmaceutical.
Clinical Role
Selected patients with symptomatic bone-metastatic CRPC without visceral metastases.
Important Qualification
Treatment requires careful assessment of marrow function, fracture risk, and appropriate bone protection.
113. PARP Inhibitors
Clinical Principle
Some prostate cancers have defects in homologous recombination DNA repair.
Important Genetic Associations
- BRCA1.
- BRCA2.
- Other homologous recombination repair genes.
Important Drugs
- Olaparib.
- Other approved PARP inhibitor regimens.
Clinical Importance
Molecular Testing Can Identify Patients With Advanced Prostate Cancer Who May Benefit From PARP Inhibitor-Based Treatment.
114. Lutetium-177 PSMA Radioligand Therapy
Definition
A radioligand treatment directed toward PSMA-expressing prostate cancer cells.
Important Agent
177Lu-PSMA-617.
Clinical Role
Selected patients with PSMA-positive metastatic CRPC, depending on previous treatment and applicable approval criteria.
115. Supportive Management of Advanced Disease
Important components include:
- Pain control.
- Bone protection.
- Management of urinary obstruction.
- Prevention and treatment of fractures.
- Management of spinal cord compression.
- Nutritional support.
- Functional rehabilitation.
- Palliative care when appropriate.
116. Prostate Cancer Prevention Trials
Prostate Cancer Prevention Trial
PCPT.
Medication
Finasteride.
Historical Finding
Approximately 23–25% reduction in prostate cancer detection.
Historical Concern
An increased proportion of high-grade cancers was detected.
Important Qualification
Subsequent analyses suggest that detection-related effects contributed to the high-grade cancer signal.
Finasteride is not routinely prescribed solely for prostate cancer prevention.
117. REDUCE Trial
Medication
Dutasteride.
Historical Finding
Reduced prostate cancer detection.
Concern
Possible high-grade cancer signal and uncertainty regarding prevention of clinically meaningful mortality.
Clinical Importance
Five-Alpha-Reductase Inhibitors Are Not Routinely Recommended Solely For Primary Prostate Cancer Prevention.
118. SELECT Trial
Full Name
Selenium and Vitamin E Cancer Prevention Trial.
Supplements Studied
- Vitamin E.
- Selenium.
Historical Termination
The trial was stopped early because of lack of benefit.
Later Findings
Vitamin E supplementation was associated with increased prostate cancer risk.
Clinical Importance
Vitamin E And Selenium Supplements Should Not Be Recommended As Proven Methods Of Preventing Prostate Cancer.
119. Lifestyle and Prevention
The source suggests:
- Reduced excessive saturated fat intake.
- Increased dietary fiber.
- Regular exercise.
- Healthy eating patterns.
Important Qualification
These are reasonable general health measures, but no particular food, antioxidant, or supplement has been proven to prevent prostate cancer.
120. Prognosis
Main Prognostic Factors
- PSA.
- Grade Group.
- Clinical stage.
- Metastatic status.
- Surgical margins.
- Seminal vesicle invasion.
- Extraprostatic extension.
- Lymph node involvement.
- Treatment response.
121. Adverse Prognostic Features
The historical source identifies:
- PSA at least 10 ng/mL.
- Gleason score 7 or higher.
- Stage T3 or greater.
- Positive surgical margins.
- Seminal vesicle invasion.
- Capsular penetration.
- Lymph node metastases.
Important Qualification
These features carry differing degrees of risk and should be combined into validated risk models where appropriate.
122. Genomic Prognostic Markers
Contemporary tissue-based genomic assays may help estimate recurrence or progression risk in selected situations.
Important Qualification
These tools supplement rather than replace:
- PSA.
- Grade Group.
- Stage.
- MRI.
- Other established prognostic factors.
123. Disease-Related Complications
Important complications include:
- Bladder outlet obstruction.
- Urinary retention.
- Hematuria.
- Bone pain.
- Pathological fractures.
- Spinal cord compression.
- Ureteral obstruction.
- Renal impairment.
Clinical Importance
Ureteral obstruction may result from locally advanced or metastatic disease.
124. Surgery-Related Complications
Urinary Incontinence
May occur following prostatectomy.
Erectile Dysfunction
May result from injury to neurovascular structures.
Other Complications
- Bleeding.
- Infection.
- Anastomotic stricture.
125. Radiation-Related Complications
Possible complications include:
- Dysuria.
- Urinary frequency.
- Urinary urgency.
- Hematuria.
- Radiation proctitis.
- Rectal bleeding.
- Erectile dysfunction.
- Urethral stricture.
126. ADT-Related Complications
Important adverse effects include:
- Hot flushes.
- Loss of libido.
- Erectile dysfunction.
- Fatigue.
- Reduced muscle mass.
- Increased fat mass.
- Osteoporosis.
- Metabolic disturbances.
- Cardiovascular risk considerations.
127. Chemotherapy-Related Complications
Important complications include:
- Neutropenia.
- Febrile neutropenia.
- Sepsis.
- Peripheral neuropathy.
- Fatigue.
- Gastrointestinal toxicity.
128. Follow-Up After Radical Prostatectomy
Historical Schedule
PSA:
Every 6–12 Months for Five Years, Then Annually.
Expected PSA
Usually undetectable.
Clinical Importance
An increasing PSA after surgery may indicate biochemical recurrence.
129. Follow-Up After Radiotherapy
PSA generally falls gradually.
Historical Favorable Prognostic Marker
The source describes a PSA nadir below:
0.5 ng/mL.
Important Qualification
A PSA nadir below 0.5 ng/mL is a favorable historical response marker rather than a mandatory definition of successful radiotherapy.
130. Biochemical Recurrence Definitions
After Radical Prostatectomy
Conventionally:
PSA ≥0.2 ng/mL with confirmation.
After Radiotherapy
PSA Nadir + 2 ng/mL.
Clinical Importance
The Definitions Of Biochemical Recurrence Differ After Prostatectomy And Radiotherapy.
131. Digital Rectal Examination During Follow-Up
The historical source recommends DRE every other year.
Contemporary Qualification
Follow-up examination should be individualized.
Routine DRE may have limited additional value when PSA remains stable and no concerning clinical findings are present.
132. Follow-Up Imaging
The source recommends imaging for:
- New bone pain.
- Rapid PSA rise.
- Short PSA doubling time.
Contemporary Imaging Options
- PSMA PET/CT.
- Prostate or pelvic MRI.
- CT.
- Bone scan in selected circumstances.
Clinical Importance
Routine Imaging Is Usually Unnecessary In Asymptomatic Patients With Stable PSA When The Result Would Not Change Management.
133. Clinical and Surgical Pearls
Epidemiology
- Prostate cancer is a common male malignancy.
- Risk increases with age.
- Family history is important.
- A substantial proportion of patients have indolent disease.
Pathology
- More Than 95% Are Adenocarcinomas.
- Most arise in the peripheral zone.
- Loss of the basal cell layer is an important histological feature.
- Gleason grading and ISUP Grade Groups guide prognosis.
Screening
- PSA is not cancer-specific.
- Risk-adapted screening is preferred.
- Family history and inherited pathogenic variants influence screening decisions.
- PSA velocity alone should not determine biopsy.
Diagnosis
- Prostate MRI Before Biopsy Is Recommended In Appropriate Patients.
- MRI-targeted sampling improves diagnostic assessment.
- Transperineal biopsy reduces infection risk.
- Pathology establishes diagnosis and Grade Group.
Staging
- Use the TNM system.
- PSA, Grade Group, and stage determine risk.
- Bone metastases are often osteoblastic.
- PSMA PET/CT improves metastatic staging.
Localized Disease
- Active surveillance is standard for suitable low-risk disease.
- Selected favorable intermediate-risk patients may also undergo surveillance.
- Radical prostatectomy and radiotherapy are established curative treatments.
- Treatment selection must consider urinary and sexual outcomes.
Advanced Disease
- ADT remains foundational.
- Fit patients with metastatic hormone-sensitive cancer usually benefit from combination therapy.
- mCRPC requires stage- and treatment-specific systemic therapy.
- Molecular testing may identify candidates for targeted treatment.
134. Essential Examination and Clinical Principles
1. Know the Most Common Histology
Prostatic adenocarcinoma.
2. Know the Most Common Anatomical Site
Peripheral zone.
3. Recognize the Importance of Family History
Especially early-onset prostate cancer or associated hereditary cancers.
4. Understand PSA Limitations
Elevated PSA is not specific for cancer.
5. Use MRI to Guide Biopsy Decisions
Prebiopsy MRI is a key contemporary diagnostic investigation.
6. Prefer Appropriate Transperineal Sampling
The principal advantage is lower infectious risk.
7. Know the ISUP Grade Groups
Gleason 3 + 4 differs prognostically from 4 + 3.
8. Recognize High-Risk Histology
Cribriform or intraductal carcinoma may preclude active surveillance.
9. Use Appropriate Staging
PSMA PET/CT is valuable in high-risk and locally advanced disease.
10. Offer Active Surveillance for Suitable Low-Risk Cancer
Avoid unnecessary treatment in patients with favorable disease.
11. Distinguish Active Surveillance From Watchful Waiting
The former preserves curative intent; the latter emphasizes symptom control.
12. Know the Main Curative Treatments
Radical prostatectomy and radiotherapy.
13. Combine Radiotherapy With ADT When Indicated
Short-term ADT for selected intermediate-risk disease and long-term ADT for high-risk disease.
14. Intensify Treatment for Most Fit Patients With Metastatic Hormone-Sensitive Disease
ADT alone is generally inadequate.
15. Recognize Castration Resistance
Progression despite castrate testosterone.
16. Understand Targeted Therapy
BRCA and other DNA repair abnormalities may influence use of PARP inhibitors.
17. Identify Spinal Cord Compression Immediately
This is an oncological emergency.
18. Maintain Long-Term PSA Surveillance
Recurrence may occur years after treatment.
135. Historical Clinical Context and Important Qualifications
Historical Incidence and Mortality
The source reports United States statistics from 2014.
These should not be presented as current epidemiological estimates.
Racial and Geographic Differences
The original figures reflect historical populations and screening practices.
Individual clinical risk should be assessed without assuming that population ancestry alone determines disease behavior.
Genetic Susceptibility
Several genes listed in the source are historical candidate genes.
Contemporary hereditary assessment places greater clinical emphasis on validated cancer-predisposition genes and molecular treatment implications.
Vitamin D
The source suggests vitamin D may be protective.
This has not been established as a reliable prostate cancer prevention strategy.
HGPIN and ASAP
Historical repeat-biopsy risk estimates should be interpreted using modern MRI-based diagnostic pathways.
PSA Velocity
The historical threshold of 2 ng/mL/year should not be used as the sole reason for biopsy.
Prostate MRI
The source describes MRI as an emerging investigation.
Prebiopsy MRI is now a major component of contemporary diagnosis.
Biopsy Technique
The historical source describes systematic TRUS biopsy as standard.
Transperineal MRI-directed approaches are now preferred in European guidance.
Localized Risk Classification
The original three-tier NCCN risk grouping has evolved.
Contemporary assessment separates favorable and unfavorable intermediate-risk disease and more precisely incorporates Grade Group and stage.
Hypofractionation
The source describes it as investigational.
Moderate hypofractionation is now established.
Cryotherapy and HIFU
The original chapter describes these as local treatment options.
Routine use remains limited by the quality and maturity of long-term comparative evidence.
Metastatic Treatment
The historical chapter emphasizes ADT alone.
Current management generally uses treatment intensification for fit patients with metastatic hormone-sensitive disease.
Castration-Resistant Disease
The original systemic therapy list predates newer molecularly targeted combinations and PSMA-directed radioligand treatment.
Vitamin E and Selenium
The SELECT trial did not show preventive benefit, and vitamin E supplementation was associated with increased prostate cancer risk.
136. Historical Diagnostic Codes
ICD-9
185
Malignant neoplasm of prostate.
601.9
Prostatitis, unspecified.
V16.42
Family history of malignant neoplasm of prostate.
ICD-10 Codes Listed in the Source
C61
Malignant neoplasm of prostate.
N41.9
Inflammatory disease of prostate, unspecified.
Z80.42
Family history of malignant neoplasm of prostate.
Coding Qualification
These codes are retained from the historical source. Clinical coding should reflect the confirmed diagnosis and currently applicable coding classification.
Final Urological Revision Summary
Prostate cancer is a biologically heterogeneous malignancy that most commonly arises as adenocarcinoma within the peripheral zone of the prostate.
Main Risk Factors
- Increasing age.
- Family history.
- Inherited cancer-predisposition variants.
- Population-associated risk factors.
- Other genetic and environmental influences.
Important Diagnostic Investigations
- PSA.
- Digital rectal examination.
- Risk assessment.
- Prostate MRI.
- Targeted and/or systematic prostate biopsy.
- ISUP grading.
- TNM staging.
- PSMA PET/CT when indicated.
Main Localized Treatment Options
- Active surveillance.
- Watchful waiting.
- Radical prostatectomy.
- External-beam radiotherapy.
- Brachytherapy.
- Selected focal treatments within appropriate specialist frameworks.
Main Advanced-Disease Treatments
- Androgen-deprivation therapy.
- Androgen receptor pathway inhibitors.
- Docetaxel.
- Selected triplet therapy.
- Cabazitaxel.
- PARP inhibitors.
- Radium-223.
- Lutetium-177 PSMA therapy.
- Immunotherapy in selected patients.
Main Prognostic Factors
- PSA.
- Grade Group.
- Clinical stage.
- Metastatic disease burden.
- Surgical pathological features.
- PSA response and kinetics.
- Molecular characteristics in selected patients.
Main Complications
Disease-related
- Bladder outlet obstruction.
- Ureteral obstruction.
- Bone pain.
- Fractures.
- Spinal cord compression.
Treatment-related
- Urinary incontinence.
- Erectile dysfunction.
- Rectal toxicity.
- Osteoporosis.
- Metabolic complications.
- Cardiovascular concerns.
- Chemotherapy-related neutropenia and sepsis.
Main Follow-Up Priorities
- Serial PSA.
- Clinical symptoms.
- Urinary function.
- Sexual function.
- Metastatic progression assessment when indicated.
- ADT toxicity monitoring.
- Bone and metabolic health.
The Central Urological Objective Is To Detect Clinically Significant Prostate Cancer Accurately, Avoid Overtreatment Of Indolent Disease, Select Curative Treatment According To Risk And Life Expectancy, Apply Appropriate Systemic Treatment For Advanced Disease, And Preserve Urinary, Sexual, Skeletal, And Overall Health Through Long-Term Follow-Up.
This chapter has been comprehensively paraphrased, including the original epidemiology, risk factors, historical genetics, pathology, screening, diagnosis, staging, localized and advanced treatments, prognosis, complications, and clinical pearls. Historical values and treatments are distinguished from contemporary recommendations. Author names, references, and additional reading have been omitted. No tables have been used.